Celon Pharma S.A. (WSE: CLN)

Celon Pharma Balance Sheet

Financials in millions PLN. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	45.13	32.36	82.9	147.8	43.98	66.69
Short-Term Investments	75.97	82.18	81.72	79.76	-	-
Cash & Short-Term Investments	121.09	114.54	164.62	227.55	43.98	66.69
Cash Growth	8.22%	-30.42%	-27.65%	417.42%	-34.06%	-54.94%
Accounts Receivable	48.49	32.79	27.11	24.67	32.53	39.18
Other Receivables	7.11	15.45	6.59	2.57	9.49	6.6
Receivables	55.61	48.24	33.7	27.25	42.02	45.78
Inventory	26.32	26.41	38.39	23.38	29.76	30.06
Other Current Assets	3.68	0.56	0.87	0.53	3.48	1.04
Total Current Assets	206.69	189.75	237.58	278.7	119.24	143.58
Property, Plant & Equipment	323.81	333.8	341.59	316.57	313.8	230.08
Long-Term Investments	14.77	11.42	13.25	38.12	12.87	48.53
Other Intangible Assets	11.61	14.29	21.15	27.81	38.38	2.08
Long-Term Deferred Tax Assets	19.18	19.05	28.14	31.94	27.17	11.5
Long-Term Deferred Charges	-	0.68	0.68	1.36	2.72	4.08
Other Long-Term Assets	0.27	0.32	0.38	12.64	17.7	151.5
Total Assets	576.33	569.31	642.76	707.14	531.89	591.35
Accounts Payable	14.91	10.51	17.47	11.87	18.42	7.36
Accrued Expenses	8.61	7.39	6.8	3.11	6.77	1.49
Short-Term Debt	-	12.75	-	-	12.84	-
Current Portion of Leases	7.56	7.13	19.43	6.56	3.49	1.47
Current Income Taxes Payable	0.6	-	-	-	-	1.02
Current Unearned Revenue	21.34	31.09	56.42	55.83	45.78	3.11
Other Current Liabilities	26.29	17.48	16.32	8.99	26.86	11.53
Total Current Liabilities	79.3	86.34	116.44	86.36	114.15	25.98
Long-Term Leases	7.69	5.71	7.39	8.35	9.16	0.19
Long-Term Unearned Revenue	21.48	22.88	25.62	29.85	39.67	108.62
Long-Term Deferred Tax Liabilities	2.37	3.01	1.32	6.04	-	11.51
Other Long-Term Liabilities	6.11	5.81	12.35	22.53	24.38	0
Total Liabilities	116.96	123.75	163.12	153.14	187.36	146.31
Common Stock	5.11	5.11	5.1	5.1	4.5	4.5
Additional Paid-In Capital	511.02	543.23	587.1	613.51	393.12	234.45
Retained Earnings	-104.21	-108.64	-119.79	-91.67	-58.57	172.34
Comprensive Income & Other	47.45	5.85	7.23	27.07	5.48	33.75
Shareholders' Equity	459.37	445.56	479.65	554	344.53	445.04
Total Liabilities & Equity	576.33	569.31	642.76	707.14	531.89	591.35
Total Debt	15.25	25.59	26.82	14.92	25.48	1.66
Net Cash (Debt)	105.84	88.95	137.8	212.63	18.5	65.03
Net Cash Growth	17.48%	-35.45%	-35.19%	1049.56%	-71.56%	-56.06%
Net Cash Per Share	2.07	1.74	2.70	4.55	0.41	1.45
Filing Date Shares Outstanding	53.86	51.06	51.04	51	45	45
Total Common Shares Outstanding	51.06	51.06	51.04	51	45	45
Working Capital	127.39	103.41	121.14	192.34	5.1	117.6
Book Value Per Share	9.00	8.73	9.40	10.86	7.66	9.89
Tangible Book Value	447.76	431.26	458.5	526.19	306.16	442.96
Tangible Book Value Per Share	8.77	8.45	8.98	10.32	6.80	9.84
Land	6.35	6.35	6.35	6.35	6.35	6.35
Buildings	146.4	146.4	146.35	146.08	173.5	54.94
Machinery	199.23	198.61	190.43	177.34	164.34	148.3
Construction In Progress	77.7	79.95	74.3	50.63	31.5	95.4

Source: S&P Capital IQ. Standard template. Financial Sources.